Health Care Select Sector SPDR Fund
Tracks S&P Health Care Select Sector
The four numbers that price an ETF.
What the ETF actually owns.
From the most recent SEC N-PORT filing. The top-10 weight tells you how concentrated the fund is — broad-market trackers run 25-30%, single-theme funds often 50-70%.
| # | Holding | Weight | Value (USD) | Asset class |
|---|---|---|---|---|
| 1 | Eli Lilly & Co | 13.74% | $5.30 B | EC |
| 2 | Johnson & Johnson | 11.10% | $4.29 B | EC |
| 3 | AbbVie Inc | 7.25% | $2.80 B | EC |
| 4 | Merck & Co Inc | 5.63% | $2.17 B | EC |
| 5 | UnitedHealth Group Inc | 4.62% | $1.78 B | EC |
| 6 | Amgen Inc | 3.57% | $1.38 B | EC |
| 7 | Thermo Fisher Scientific Inc | 3.48% | $1.34 B | EC |
| 8 | Abbott Laboratories | 3.37% | $1.30 B | EC |
| 9 | Gilead Sciences Inc | 3.26% | $1.26 B | EC |
| 10 | Intuitive Surgical Inc | 3.09% | $1.19 B | EC |
| 11 | Pfizer Inc | 3.01% | $1.16 B | EC |
| 12 | Bristol-Myers Squibb Co | 2.33% | $899 M | EC |
| 13 | Danaher Corp | 2.25% | $868 M | EC |
| 14 | Vertex Pharmaceuticals Inc | 2.14% | $825 M | EC |
| 15 | Stryker Corp | 2.13% | $824 M | EC |
| 16 | Medtronic PLC | 2.09% | $808 M | EC |
| 17 | McKesson Corp | 2.00% | $771 M | EC |
| 18 | Boston Scientific Corp | 1.75% | $677 M | EC |
| 19 | CVS Health Corp | 1.72% | $665 M | EC |
| 20 | Regeneron Pharmaceuticals Inc | 1.47% | $567 M | EC |
| 21 | HCA Healthcare Inc | 1.40% | $539 M | EC |
| 22 | Cigna Group/The | 1.32% | $511 M | EC |
| 23 | Elevance Health Inc | 1.22% | $470 M | EC |
| 24 | Cencora Inc | 1.15% | $445 M | EC |
| 25 | Zoetis Inc | 0.94% | $363 M | EC |
What we measure and what we leave out.
Data sources: SEC EDGAR N-PORT filings (holdings + filing-date timestamp); issuer fact sheets for expense ratio + AUM + inception; Yahoo Finance for daily NAV.
Expense ratio is the single biggest forward predictor of long-horizon performance. A 0.03% expense ratio compounds to a fundamentally different outcome than a 0.95% expense ratio over 25 years — even if the underlying index is identical.
Concentration risk lives in the top-10 weight. For broad-market trackers (VOO, VTI, SPY) the top-10 sits around 28-32%. For thematic funds — semiconductors, AI, cannabis — top-10 often crosses 60%. A "sector tilt" with 60% in 10 names is closer to active stock-picking than passive index exposure.
LRS + tax for Indian investors: US-listed ETFs are securities for Indian-tax purposes — held > 24 months = LTCG @ 12.5%, ≤ 24 months = slab-rate STCG. Distributions are dividends taxed at slab rates (US withholds 25%, creditable via DTAA). LRS USD 250,000 / FY cap applies to each remittance.
India-listed alternative: for S&P 500 / NASDAQ-100 exposure without LRS friction, see India-listed ETFs at /etfs/ (Motilal Oswal, Mirae, Nippon, etc. variants). Higher TER but no LRS hassle and INR-settled.
What this page does not model: tracking error vs underlying index, premium/discount to NAV, bid-ask spread on-exchange, currency-hedged variants (e.g. JPST-hedged), securities lending revenue (which subsidises some expense ratios).
ETF NAVs, tracking error and AUM are computed from AMFI disclosures. ETFs are subject to market risk and tracking-error risk. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.